Biogen discontinues Aduhelm to focus on Leqembi for Alzheimer’s disease
The goal had been for 10,000 patients to be on Leqembi by the end of March 2024, but only 2,000 patients received the drug as of 26 January.
The goal had been for 10,000 patients to be on Leqembi by the end of March 2024, but only 2,000 patients received the drug as of 26 January.
What's Your Reaction?
